Key facts
- Graph Therapeutics Flex’s last known valuation is $14.5M (Jan 2025).
- It has raised $3.1M; the latest was Seed Round ($3.1M) in Jan 2025.
- Notable investors include Mehdi Ghissassi, Merantix Capital, NAVEC Investment Management, SquareOne Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Graph Therapeutics Flex
- ·The full record, as it builds
Funding rounds
No funding rounds for Graph Therapeutics Flex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Graph Therapeutics Flex
Developer of AI-driven precision medicine designed for perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. The company leverages artificial intelligence to analyze a patient's unique biology to create personalized treatment plans for immune-mediated diseases, enabling the healthcare industry to overcome the unique challenges of developing therapies for complex inflammatory diseases.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2024
- Employees
- 16
- Website
- graphtx.com/
- Ownership
- Privately Held (backing)
Graph Therapeutics Flex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Graph Therapeutics Flex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Graph Therapeutics Flex in its N-PORT filings yet. We sweep new filings monthly.